Sep. 16 at 3:22 PM
$FBIO + (
$DERM )
Older copper injections, sometimes prepared in-house, could be painful and, with long-term use, could cause kidney damage. In clinical trials for CUTX-101, adverse events were generally not considered related to the study treatment, highlighting its improved safety profile.
Enhanced bioavailability and safety
The specific formulation of CUTX-101 ensures better delivery of copper to the body and brain, where it is critically needed.
CUTX-101 has been granted Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations. These designations recognize the drug's potential to provide significant clinical improvement over existing treatments for a rare condition with unmet medical needs.
$DERM ( subsidiary of
$FBIO OWNS ACCUTANE, see screenshots and link for how it helps treat male infertility .
https://www.livescience.com/health/fertility-pregnancy-birth/acne-drug-accutane-may-restore-sperm-production-in-infertile-men-early-study-hints
$BIB $JNJ
